Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicover ABLTS:0RPS +1.31%87 EV-to-EBITDA is 11.66 as of Aug. 12, 2026, which is 14% below its 10-year median of 13.53. GuruFocus rates LTS:0RPS with a GF Score™ of 87/100 and a GF Value™ of kr232.40 (Fairly Valued). The stock has 5 warning signs investors should review. Among 513 Healthcare Providers & Services companies, Medicover AB ranks worse than 53.61% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medicover AB's enterprise value is kr50,215 Mil.
Medicover AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr4,307 Mil. Therefore, Medicover AB's EV-to-EBITDA for today is 11.66.
The historical rank and industry rank for Medicover AB's EV-to-EBITDA or its related term are showing as below:
LTS:0RPS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.48 Med: 13.53 Max: 26.49
Current: 11.66
During the past 12 years, the highest EV-to-EBITDA of Medicover AB was 26.49. The lowest was 9.48. And the median was 13.53.
LTS:0RPS's EV-to-EBITDA is ranked worse than 53.61% of 513
companies
in the Healthcare Providers & Services industry
Industry Median: 10.81
vs LTS:0RPS: 11.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medicover AB's PE Ratio (TTM) for today is calculated as:
Medicover AB's share price for today is kr231.50.
Medicover AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr6.106.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medicover AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RPS vs HCA, THC, DVA: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Medicover AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicover AB EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medicover AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medicover AB's EV-to-EBITDA falls into.
Medicover AB's current Enterprise Value is kr50,215 Mil.
Medicover AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr4,307 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicover AB (LTS:0RPS) has a EV-to-EBITDA of 11.66 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medicover AB. This is 14% below median its historical median of 13.53. Over the past decade, Medicover AB's EV-to-EBITDA has ranged from 9.48 to 26.49. According to the industry distribution chart, Medicover AB ranks #275 out of 513 companies in the Healthcare Providers & Services industry, placing it in the top 53.6%.
Is Medicover AB's EV-to-EBITDA too high?
Medicover AB's current EV-to-EBITDA of 11.66 is 14% below median its 10-year median of 13.53. Over the past 10 years, this metric has ranged from a low of 9.48 to a high of 26.49. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.81. Medicover AB's value of 11.66 is 7.9% above this industry median. Based on the distribution chart, Medicover AB ranks #275 out of 513 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Medicover AB has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medicover AB's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Medicover AB ranks #275 out of 513 companies for EV-to-EBITDA. This places Medicover AB in the lower half of its industry. The industry median EV-to-EBITDA is 10.81. Medicover AB's value of 11.66 is 7.9% above this benchmark. Historically, Medicover AB's own EV-to-EBITDA has ranged from 9.48 to 26.49 over the past decade. While the company's 10-year median is 13.53 vs. the industry median of 10.81, Medicover AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.81, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicover AB's current EV-to-EBITDA of 11.66 is 7.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medicover AB. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicover AB's current EV-to-EBITDA is 11.66, which is 14% below median its own 10-year median of 13.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicover AB stock overvalued right now?
Based on GuruFocus' analysis, Medicover AB (LTS:0RPS) is currently considered Fairly Valued. The stock's GF Value™ is kr232.40, compared to a current price of kr231.50 — trading 0.4% below its estimated fair value. The current EV-to-EBITDA is 11.66, which is 14% below median its 10-year median of 13.53 and 7.9% above the Healthcare Providers & Services industry median of 10.81. Medicover AB's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medicover AB (LTS:0RPS), the current EV-to-EBITDA is 11.66 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicover AB (LTS:0RPS) Overvalued in 2026?
Based on GuruFocus' analysis, Medicover AB stock appears to be undervalued.
The current stock price of kr231.50 is trading 0.4% below its estimated GF Value™ of kr232.40.
GuruFocus considers Medicover AB to be Fairly Valued.
Key valuation signals for LTS:0RPS:
EV-to-EBITDA: 11.66 (14% below median its 10-year median of 13.53)
GF Value™: kr232.40 vs. price of kr231.50 (0.4% below fair value)
Industry Position: 7.9% above the Healthcare Providers & Services median (#275 of 513)
No single metric tells the full story. See the LTS:0RPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicover AB is an international healthcare and diagnostic services provider. It offers a broad spectrum of healthcare services via an extensive network of ambulatory clinics, hospitals, specialty-care facilities, and laboratories. Medicover offers its services through two reportable segments: Healthcare Services, which generates the maximum revenue, and Diagnostic Services. Diagnostic Services offer a broad range of laboratory testing in all clinical pathology areas, and Healthcare Services offer medical care and related services by operating on an Integrated Healthcare and Fee-For-Service model across different countries. Geographically, the company derives maximum revenue from Germany, and the rest from Poland, India, Ukraine, Romania, and other countries.
87GF Score
Get the complete analysis for LTS:0RPS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RPS has been successfully added to your 
